Research progress of peptide receptor radionuclide therapy combined with other drugs in the treatment of neuroendocrine tumors
10.3760/cma.j.cn321828-20210416-00122
- VernacularTitle:肽受体放射性核素疗法联合药物治疗神经内分泌肿瘤研究进展
- Author:
Limeng HE
1
;
Ying DENG
;
Anbo WANG
;
Nan LIU
;
Yue CHEN
;
Wei ZHANG
Author Information
1. 西南医科大学附属医院核医学科、核医学与分子影像四川省重点实验室，泸州 646000
- Keywords:
Neuroendocrine tumors;
Receptors, peptide;
Receptors, somatostatin;
Drug therapy;
Trends
- From:
Chinese Journal of Nuclear Medicine and Molecular Imaging
2022;42(11):692-695
- CountryChina
- Language:Chinese
-
Abstract:
Peptide receptor radionuclide therapy (PRRT) is a nuclear medicine method that uses radionuclide-labeled somatostatin analogs (SSAs) to image and treat tumors overexpressing somatostatin receptor (SSTR). For the treatment of neuroendocrine tumors (NETs), PRRT alone can achieve a high disease control rate (DCR), but with a low disease response rate (DRR). Studies have shown that, PRRT combined with SSAs such as octreotide and lanreotide, PRRT combined with chemotherapy drugs such as 5-fluorouracil, capecitabine and temozolomide, PRRT combined with targeted drugs such as tarazopinib, everolimus and heat shock protein inhibitors, PRRT combined with immune drugs such as navumab, and the combination of 177Lu-1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacceticacid (DOTA)-Tyr3-octreotide (TOC)/DOTA- D-Phe1-Tyr3-Thr8-octreotide (TATE) and 90Y-DOTATOC/DOTATATE, are promising to improve the efficacy of PRRT in the treatment of NETs with tolerable side effects. These PRRT combinations demonstrate an encouraging potential to improve clinical outcomes in NETs patients, and more prospective randomized clinical trials are needed to further validate current findings.
